Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382354 | 0.85 | TKT (0.48) | TKTLMNADRD4ALDH1A1CYP3A4 | |
| SCHEMBL4382783 | 0.81 | TKT (0.51) | TKTLMNADRD4ALDH1A1CYP3A4 | |
| SCHEMBL13603026 | 0.76 | MAPK14 (0.52) | — | |
| SCHEMBL13602966 | 0.74 | MAPK14 (0.68) | — | |
| Hydrochloric Acid SCHEMBL4382509 | 0.74 | MAPK14 (0.67) | — | |
| Hydrochloric Acid SCHEMBL29593377 | 0.74 | MAPK14 (0.67) | — | |
| Trifluoroacetic Acid SCHEMBL4376502 | 0.73 | MAPK14 (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL4376011 | 0.72 | MAPK14 (0.62) | — | |
| SCHEMBL4376097 | 0.72 | TLR7 (0.40) | — | |
| SCHEMBL4381562 | 0.71 | MAPK14 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | TKT 1722/4885LMNA 1815/4885CGAS 1119/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | TKT 1431/4885LMNA 1884/4885CGAS 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.